ALX Oncology Holdings Inc.
Organization details
- Legal name
- ALX Oncology Holdings Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- South SAN Francisco
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- ALXO
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001810182
- EIN
- 85-0642577
Board of directors
-
Alan B. Sandler · DirectorSince 2024
-
Barbara Klencke · DirectorSince 2025
-
Chris H. Takimoto · DirectorSince 2025
-
Corey S. Goodman · DirectorSince 2023
-
Daniel J. Curran · DirectorSince 2025
-
Itziar Canamasas · DirectorSince 2023
-
J. Scott Garland · DirectorSince 2023
-
Jack Nielsen · DirectorSince 2023
-
Jason Lettmann · Director · CHIEF EXECUTIVE OFFICERSince 2023
-
Jaume Pons · Director · PRESIDENT & CSOSince 2023
-
Rekha Hemrajani · DirectorSince 2023
-
Sophia Randolph · Director · CHIEF MEDICAL OFFICERSince 2023
Chief executives
Director election results
Annual meeting of June 10, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
81.9%
-
99.9%
Board connections
5 of this board's directors also sit on 11 other boards. 11 are in the same sector.
-
LB Pharmaceuticals Inc Same sectorvia J. Scott Garland and Rekha Hemrajani
-
Aligos Therapeutics Inc. Same sectorvia Jack Nielsen
-
BioAge Labs Inc. Same sectorvia Rekha Hemrajani
-
Enliven Therapeutics Inc. Same sectorvia J. Scott Garland
-
Harmony Biosciences Holdings Inc. Same sectorvia Jack Nielsen
-
Instil Bio Inc. Same sectorvia Jack Nielsen
-
MaxCyte Inc. Same sectorvia Rekha Hemrajani
-
Olema Pharmaceuticals Inc. Same sectorvia J. Scott Garland
-
TScan Therapeutics Inc. Same sectorvia Barbara Klencke
-
Xencor Inc. Same sectorvia Barbara Klencke
-
Xilio Therapeutics Inc. Same sectorvia Daniel J. Curran
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $4,999,999
- 1 purchase by 1 insider
- Sold, last 12 months
- $42,588
- 7 sales by 2 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 17, 2026 | Wong Shelly Officer (SVP, FINANCE AND CAO) | Open-market sale | −573 | $1.93 | $1,106 |
| Aug 17, 2026 | Jason Lettmann Director, Officer (CHIEF EXECUTIVE OFFICER) | Open-market sale | −2,230 | $1.93 | $4,304 |
| Jul 1, 2026 | Wong Shelly Officer (SVP, FINANCE AND CAO) | Open-market sale | −1,404 | $2.04 | $2,864 |
| Mar 19, 2026 | Jason Lettmann Director, Officer (CHIEF EXECUTIVE OFFICER) | Open-market sale | −12,311 | $2.17 | $26,715 |
| Mar 19, 2026 | Pinto Shelly Officer (SVP, FINANCE AND CAO) | Open-market sale | −903 | $2.17 | $1,960 |
| Feb 18, 2026 | Pinto Shelly Officer (SVP, FINANCE AND CAO) | Open-market sale | −565 | $2.27 | $1,283 |
| Feb 17, 2026 | Jason Lettmann Director, Officer (CHIEF EXECUTIVE OFFICER) | Shares withheld for tax | −2,201 | $2.27 | $4,996 |
| Feb 2, 2026 | Corey S. Goodman Director, 10% owner | Open-market purchase | +3,184,713 | $1.57 | $4,999,999 |
| Jan 6, 2026 | Pinto Shelly Officer (SVP, FINANCE AND CAO) | Open-market sale | −3,925 | $1.11 | $4,357 |
| Sep 17, 2025 | Jason Lettmann Director, Officer (CHIEF EXECUTIVE OFFICER) | Open-market purchase | +71,163 | $1.08 | $76,856 |
| Sep 16, 2025 | Jason Lettmann Director, Officer (CHIEF EXECUTIVE OFFICER) | Open-market purchase | +21,070 | $1.07 | $22,545 |
| Aug 18, 2025 | Shantharam Harish Officer (Chief Financial Officer) | Open-market purchase | +75,000 | $0.78 | $58,500 |
| Aug 15, 2025 | Pinto Shelly Officer (SVP, FINANCE AND CAO) | Open-market sale | −611 | $0.64 | $391 |
| Aug 15, 2025 | Jason Lettmann Director, Officer (CHIEF EXECUTIVE OFFICER) | Open-market sale | −2,382 | $0.64 | $1,524 |
| Jul 7, 2025 | Pinto Shelly Officer (SVP, FINANCE AND CAO) | Open-market sale | −2,011 | $0.45 | $905 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about ALX Oncology Holdings Inc.
Who is the CEO of ALX Oncology Holdings Inc.?
Jaume Pons is ALX Oncology Holdings Inc.'s President & CEO.
How many directors are on ALX Oncology Holdings Inc.'s board?
ALX Oncology Holdings Inc.'s board has 12 directors: Alan B. Sandler, Barbara Klencke, Chris H. Takimoto, Corey S. Goodman, Daniel J. Curran, Itziar Canamasas, J. Scott Garland, Jack Nielsen, Jason Lettmann, Jaume Pons and 2 others.
Are ALX Oncology Holdings Inc. insiders buying or selling shares?
Over the last 12 months, ALX Oncology Holdings Inc. insiders bought $5.0 million of shares in 1 purchase and sold $42,588 of shares in 7 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="alx-oncology-holdings-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.